Product Reports Resources Pricing Login Book a demo

Agios Pharmaceuticals

Biotech & Life Sciences · Cambridge, United States · Founded 2008 · IPO 2013

Biopharmaceutical company discovering and developing therapeutics for cancer metabolism

Valuation $1.21B
Revenue $148M
Power Law Unicorn$1–10B valuation tier Thoroughbred$100M+ revenue

Investors

8 investors on Agios Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 2 investors entered at this stage
Flagship Pioneering
ARCH Venture Partners
Series A 1 investor entered at this stage
Third Rock Ventures
Series B+ 5 investors entered at this stage
Bristol-Myers Squibb
University of Toronto
University of Pennsylvania
Harvard University
Celgene

Agios Pharmaceuticals mafia

Startups founded by Agios Pharmaceuticals alumni

Former Agios Pharmaceuticals employees who went on to start their own companies. Sorted by Dealroom signal score.

Xaira TherapeuticsEst. 2023
Marc Tessier-LavigneUnited States
Signal score92
ELucidata.ioEst. 2015
AJAbhishek JhaUnited States
Signal score75
Auron TherapeuticsEst. 2018
Kate YenUnited States
Signal score69
Clear Creek BioEst. 2017
David ScaddenUnited States
Signal score68
Mythic TherapeuticsEst. 2017
Brian FiskeUnited States
Signal score61
Petra Pharma CorporationEst. 2016
LCLewis CantleyUnited States
Signal score55

Book a demo to explore the full alumni network →

Global footprint

Where Agios Pharmaceuticals has talent and traffic

Workforce by country
8 countries with
team presence
🇺🇸 United States96.6%
🇮🇳 India2%
🇨🇭 Switzerland0.3%
🇳🇱 Netherlands0.2%
🇮🇹 Italy0.2%
Top 5 of 8 shown
Web traffic by country
24K monthly visits
across markets
🇺🇸 United States75.4%
🇬🇧 United Kingdom5.4%
🇨🇦 Canada5%
🇮🇳 India5%
🇫🇷 France3.8%
Top 5 markets shown

Talent graph

The shape of Agios Pharmaceuticals's talent

Dealroom maps Agios Pharmaceuticals's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

15 standout operatorsDealroom-flagged across the org
4 AI specialistspinpointed by name
642 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Agios Pharmaceuticals's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$318M patent portfolio · 96 active families

Estimated portfolio value
$318M
26.3% of market cap · 2.5× smaller than top peer BioNTech ($788M)
96 active patent families
Where Agios Pharmaceuticals innovates Active compoundCancer researchCarcinosisMedicinal chemistryMolecular biology

Where Agios Pharmaceuticals concentrates vs peers

Each axis is a top-10 topic across Agios Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Agios Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Agios Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Agios Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles